Last reviewed · How we verify

NCT04945005: PLACE

Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation Registry

Completed Last updated 30 June 2021
What this trial tests

trial testing Transesophageal guidance of lead implantation in Tricuspid Valve Insufficiency in 124 participants. Completed in 31 December 2020.

Timeline
1 November 2019
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorLMU Klinikum
StatusCompleted
Study typeOBSERVATIONAL
Enrollment124
Start date1 November 2019
Primary completion31 December 2020
Estimated completion31 December 2020
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

LMU Klinikum — full company profile →

Who can join

18 and older, any sex, with Tricuspid Valve Insufficiency or Pacemaker Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Registry for patients undergoing pacemaker/ICD implantation including a transtricuspid lead with and without intraprocedural transesophageal echocardiography to evaluate risk factors for lead induced tricuspid regurgitation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tricuspid Valve Insufficiency

Currently open trials in the same condition.

Other LMU Klinikum trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04945005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing